EUPATI Update

to participants of the EUPATI Focus Groups
EUPATI Webinar
on 4 November 2013
- For presentation purposes on...
Aims of webinar







To provide webinar participants with an overview on the current status
of the EUPATI project
To...
Overview of today’s webinar
Topic

Speaker

Progress update on the status of EUPATI

Annamarie Dillon

Findings and recomm...
EUPATI Project Update
4 November 2013

For presentation purposes only, not for further dissemination
European Patients' Academy on
Therapeutic Innovation…







Public-Private Partnership of EU Commission and EFPIA
La...
By 2016, the Patients’ Academy
will…


develop and disseminate accessible, well-structured and userfriendly information a...
Audiences: Advocacy leaders as
well as the general public

1
2
3

EUPATI Certificate Training Programme
Academic Modular ...
Task Forces within EUPATI
Project Secretariat

Network
Implementation

Needs
Assessment,
Gap Analysis

Content
Development...
European Patients’ Academy:
General Progress








Website available in all 7 languages, collaboration tools esta...
European Patients’ Academy:
Progress in Work Packages










Monthly EUPATI newsletters now available and active...
Findings and
recommendations from
patient advocate focus groups
Suzanne Parsons, EUPATI WP3 Project Manager, Nowgen,
Unive...
Overview of needs assessment work
Review Work
Review of existing
information
resources on
medicines
development aimed
at p...
Aims


To explore patient advocates’ attitudes and information needs
regarding medicines development and their involvemen...
Recruitment




EUPATI meeting participants (Regional workshop; NLT meeting;
EUPATI Conference)
Information sheet and c...
Sampling



Key sampling criteria – Patient organisation with a National, European
or International focus
Reported exper...
Focus group topic guide




Medicines development experience
How patient advocates support patients’ awareness of and
i...
Focus groups undertaken




5 FGs at regional workshop in Frankfurt, September 2012
1 FG at NLT meeting in Barcelona, M...
Key Themes




Role of patient advocates in general and in relation to medicines
development
Beliefs about patient invo...
Role of patient advocates in general
Multi-faceted role
•
•
•
•
•

Support patients – day-to-day symptom management
Awaren...
Role of patient advocates in research







As participants
Recruiting participants
Providing advice about research...
Role of patient advocates in research


As participants - ‘I also took part in a study and we…only time I saw
the doctor ...
Role of patient advocates in medicines
development








Research involvement just one of the many roles played by...
Role of patient advocates in medicines
development





Relationships - All the times they [pharmaceutical companies] f...
Beliefs about patient involvement in
medicines development


Some patient advocates/expert patients want to be profession...
Information should be…








Accurate and up-to-date
Quick and easy to navigate
Easy to judge that it is high qua...
Training courses content


Increasing content knowledge will increase patients’ confidence in
getting involved in medicin...
Training courses content
Further information required on:










Science behind / scientific aspects of studie...
Training courses format






Face to face elements provide “validation”; however, there is a danger of
“decay” - not...
Delivery of training courses


Importance of using virtual methods of delivery

29
Recommendations to content
development team
Degree of emphasis placed on some modules compared to others
That the time de...
Recommendations to content
development team
Quality, credibility and impartiality of the information and training
produced...
Recommendations to content
development team
Recommendations on course content
That course content clearly describes patie...
Recommendations to deployment and
dissemination team
Recommendations on application process for expert level training
cour...
Work Package 3 team













University of Manchester
Bella Starling – WP3 lead
Suzanne Parsons – WP3 Proj...
Get to know us!

Web:
www.patientsacademy.eu

Twitter: @eupatients
as well as:
Building Knowledge & Capacities for
Patients’ Involvement in Medicines
R&D

Niels Westergaard, PhD, DSc
Biopeople
Universi...
Audiences: Advocacy leaders as
well as the general public

1
2
3

EUPATI Certificate Training Programme
Academic Modular ...
First version of the syllabus: 133 Topics

F2F and eLearning
•2 x 4 days F2F
•240 h of eLearning
Topics:
Topics:
Heavy: 2-...
Learning outcomes condensed
Basic Principles of Medicine Discovery and Development

The concept of Bioavailability and Bioequivalence
Deployment and Quality
Assurance
EUPATI Work Package 6 Update
WP6 Objectives






To implement the EUPATI expert, education and information
programmes at European and national lev...
WP6 Activities


Development and implementation of Communication Strategy for
dissemination of programmes



Programme r...
WP6 Deliverables
Progress update


Communication strategy being drafted – to be completed by end of
November



Audience 1 - Patient Expe...
Recruitment Audience 1
Eligibility








Individual Employee of a patient organisation who does not have the condi...
Recruitment Audience 1
Selection criteria
1)

Individual motivation

2)

Commitment to complete training

3)

Commitment t...
Selection procedure
1)

Review of compliance with eligibility criteria + completeness of
application package (WP6)

2)

Se...
Next steps and questions

Web:
www.patientsacademy.eu

Twitter: @eupatients
as well as:
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
Upcoming SlideShare
Loading in …5
×

Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013

445 views
320 views

Published on

Webinar of the European Patients' Academy on Therapeutic Innovation (EUPATI) held on 4 Nov 2013 to update participants of its focus groups about project progress, results of the qualitative research, and how the recommendations translate into content production and dissemination activities of the project.

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
445
On SlideShare
0
From Embeds
0
Number of Embeds
7
Actions
Shares
0
Downloads
4
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013

  1. 1. EUPATI Update to participants of the EUPATI Focus Groups EUPATI Webinar on 4 November 2013 - For presentation purposes only, not for further dissemination - The project is receiving support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115334, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies.
  2. 2. Aims of webinar     To provide webinar participants with an overview on the current status of the EUPATI project To provide feedback to webinar participants on the findings and recommendations made from the focus groups that they participated in at EUPATI events To provide details of how the findings and recommendations from this work have informed the development and implementation of the EUPATI training course for patient advocates To say thank you for your participation 2
  3. 3. Overview of today’s webinar Topic Speaker Progress update on the status of EUPATI Annamarie Dillon Findings and recommendations from needs assessment focus groups Suzanne Parsons Content development overview and response to recommendations from focus groups Niels Westergaard Deployment and dissemination overview and response to recommendations from focus groups Liuska Sanna Next steps and questions Annamarie Dillon 3
  4. 4. EUPATI Project Update 4 November 2013 For presentation purposes only, not for further dissemination
  5. 5. European Patients' Academy on Therapeutic Innovation…      Public-Private Partnership of EU Commission and EFPIA Launched February 2012, runs for 5 years Patient-led, coordinated by European Patients’ Forum, and EGAN, EURORDIS, EATG in leadership roles Will develop and disseminate objective, credible, correct and up-to-date public knowledge about medicines R&D A strong multi-stakeholder consortium of patient organisations, academia, NGOs and industry – 30 organisations
  6. 6. By 2016, the Patients’ Academy will…  develop and disseminate accessible, well-structured and userfriendly information and education on medicines R&D  build expert capacity by training patient advocates, and enhancing capacities among patients and the public  create a leading public library on medicines R&D: translated into 7 languages, published under “creative commons license”  facilitate patient involvement in R&D to partner up with academia, authorities, industry and ethics committees THAT WILL LEAD TO - a paradigm shift in empowering patients and the public to understand the medicines development process and how to contribute to it …we do not offer indicationor therapyspecific information!
  7. 7. Audiences: Advocacy leaders as well as the general public 1 2 3 EUPATI Certificate Training Programme Academic Modular Certificate Programme Patient Ambassadors in various committees, R&D teams, … Patient Journalists raising awareness Patient Trainers for patient communities & networks EUPATI Educational Toolbox   Educational tools for patient advocates Variety of distributable formats: Paper-based booklets, ppt presentations, eLearning, webinars, videos etc. 100 patient experts 12,000 patient advocates EUPATI Internet Library   Patients & the general public, eg, on specific aspects of the development process of medicines for patients with little health literacy experience Wiki, YouTube, films, cartoons, etc. 100,000 individuals
  8. 8. Task Forces within EUPATI Project Secretariat Network Implementation Needs Assessment, Gap Analysis Content Development IT Infrastructure Deployment & Quality Control Sustainability Task Forces Task Forces Task Forces Task Force 2.1 Establishment and Coordination of the EUPATI Network 4.1 Medicines development process from research to approval 5.1 Functional specification Communications Task Force 2.2 Organisation of EUPATI Conferences and Regional Workshops 4.2 Personalized and predictive medicine 5.2 Implementation of the signed-off functional specification 4.3 Drug safety and risk/benefit assessment of (novel and existing) medicines 5.3 Support and training to defined users in the organisation 4.4 Pharmacoeconomics and health technology assessment 5.4 Handover of infrastructure and hosting of the portal to EUPATI 2.3 Organisation of National Liaison Teams to support other WPs' activities 2.4 Design, management and maintenance of a digital communication platform for all Network Members 2.5 EUPATI Ethics Panel 4.5 Design and objectives of clinical trials (& involved stakeholders) 4.6 Patients' roles and responsibilities in innovative medicines development (4.7) Editorial Board
  9. 9. European Patients’ Academy: General Progress        Website available in all 7 languages, collaboration tools established Advisory Board meetings ongoing Ethics Panel established, Ethics Framework finalised “EUPATI Network” launched, National Liaison teams forming Communications: Multiple presentations at conferences, Communications plan in place First conference held in Rome in March 2013 Needs assessment data analysis underway
  10. 10. European Patients’ Academy: Progress in Work Packages        Monthly EUPATI newsletters now available and active on social media – join the discussions 10 out of 12 National Liaison Teams have drafted country maps and have plans to engage individuals and groups on a national level; April 2014 meeting in Warsaw, P, being planned Needs assessment fieldwork completed; themes have been identified and recommendations have been shared within the project Content for training course being developed IT infrastructure and web platform being designed, user testing will start soon Selection criteria and application process for training course being finalised Examples of best practices / public private partnerships have been identified, call will continue
  11. 11. Findings and recommendations from patient advocate focus groups Suzanne Parsons, EUPATI WP3 Project Manager, Nowgen, University of Manchester
  12. 12. Overview of needs assessment work Review Work Review of existing information resources on medicines development aimed at patients and the public Review of research literature on patients’ and the public’s knowledge, attitudes and beliefs regarding medicines development Online Surveys General public across 6 European countries (GB, Spain, Poland, Italy, France and Germany) Qualitative Studies Patient advocates and expert patients across Europe Of patients, public, patient advocates, pharmaceutical industry, clinical research professionals and policy makers in UK, ES, PL 470 responses from patient advocates and expert patients across Europe 148 reported current research involvement and 98 previous involvement 125 commented on PILs 70 involved in identifying research priorities 90 member of project advisory group Across all sites Final report Final report Country reports Findings 306 resources submitted. 230 included in review. Highest number of resources covering drug safety. Lowest number covering personalised and predictive medicine. 12600 titles and abstracts reviewed 134 included in review. Medicines development (1 study Personalised and predictive medicine 52 studies Medicines safety 28 studies HTA 10 studies Clinical trials 40 studies 7003 members of the public surveyed 6931 responses recorded Interest in learning more about medicines developed areas had a similar pattern in all countries •Medicines safety •Personalised and predictive medicine •Drug discovery •HTA •Clinical trials •Patients roles and responsibilities •Regulation •Pharmacoeconomics 91 patient advocates 34 members of the public 13 policy makers 20 pharmaceutical industry representatives 23 Clinical research professionals / Health care academics 181participants I total Reports Information review executive summary and full report, Interim report in Nov 2012 Evidence summary doc. Methods and data doc. Abstracts and interim report Final report Oct 2013 Methods and data document Interim report 12
  13. 13. Aims  To explore patient advocates’ attitudes and information needs regarding medicines development and their involvement in it  Qualitative research approach used: • • Useful if there is little known about an issue Best way of exploring key stakeholders’ perspectives and understanding and what an issue means to them 13
  14. 14. Recruitment    EUPATI meeting participants (Regional workshop; NLT meeting; EUPATI Conference) Information sheet and consent form Conference organisers collected • • • • Organisation type Disease area Geographical scope Experience of medicines development 14
  15. 15. Sampling   Key sampling criteria – Patient organisation with a National, European or International focus Reported experience of medicines development (some experience versus no experience) 15
  16. 16. Focus group topic guide    Medicines development experience How patient advocates support patients’ awareness of and involvement in medicines development Patient advocates information, training and support needs to increase patients’ awareness of and involvement in medicines development • •  For patient advocates For patients at large Barriers and facilitators to developing and / or improving patient information 16
  17. 17. Focus groups undertaken    5 FGs at regional workshop in Frankfurt, September 2012 1 FG at NLT meeting in Barcelona, March 2013 2 FGs at EUPATI conference in Rome, April 2013 53 patient advocates took part overall 17
  18. 18. Key Themes    Role of patient advocates in general and in relation to medicines development Beliefs about patient involvement in the medicines development process Beliefs about information needs regarding the medicines development process • • •  Training course content Training course format Additional areas which EUPATI Should cover Beliefs about the quality and trustworthiness of the training and information produced by EUPATI 18
  19. 19. Role of patient advocates in general Multi-faceted role • • • • • Support patients – day-to-day symptom management Awareness raising of condition Producing and disseminating information Managing patient expectations regarding new treatments Involvement in research 19
  20. 20. Role of patient advocates in research       As participants Recruiting participants Providing advice about research participation Facilitating links between doctors, patients, scientists and the pharmaceutical industry Influencing on a regulatory level Being co-researchers • • • • Organisers Funders Influencing research priorities Developing patient information 20
  21. 21. Role of patient advocates in research  As participants - ‘I also took part in a study and we…only time I saw the doctor was one evening, had a doctor and study nurse explain the study. And then I had to go to the study nurse every time’  Recruiting participants - ‘I've participated in a short term clinical trial myself but then I spent most of my time, like five years helping other patients get into clinical trials’.  Providing advice about participation – ‘We added all the clinical trials which are going on and we informed the patient from the early beginning what it means being part of a clinical trial. And now for our organisation we have the same, we are working together with our registry and they are all the specialists, the researchers; and we can provide all our patients with ongoing trials’ 21
  22. 22. Role of patient advocates in medicines development       Research involvement just one of the many roles played by patient advocates Need for realism and recognition of how patients can incorporate playing an active role in medicine R&D into their many other roles Importance of clarifying and communicating the roles that patients can play in medicines development Relationships are vitally important – everybody (including patients, industry and academia) needs training in how to communicate with each other, work together and respect one another’s perspectives Feeling that industry can be unapproachable Health professional still act as the gatekeeper to industry for many patients 22
  23. 23. Role of patient advocates in medicines development    Relationships - All the times they [pharmaceutical companies] forget to talk with the patients’ organisations first’ Perceptions of industry - I was with a pharmaceutical company in Germany about a year ago, and they were developing a new medication. They wouldn’t give us any information. They wouldn’t let us anywhere near it. No cameras, nothing. They said it was all commercially sensitive’. Health professional as gatekeeper to industry - ‘Sometimes, depends on the physicians. How do they inform the patients? If they are open to information, they do follow the path of education on that. If they do not inform them, they just don’t know what they are going through. So it’s patients’ position depends on many other factors, not just physicians’ approach…But in general, it’s basically still in the hands of physicians, how they prepare patients for that occasion.’ 23
  24. 24. Beliefs about patient involvement in medicines development  Some patient advocates/expert patients want to be professionalised, others don't •  Feeling amongst some that having to take an accredited course could be a barrier. •   “If I don't do it, I won't be seen as an expert, but I already am”. Importance of patients’ knowledge about their own conditions being taken into account and valued •  “I agree you have to professionalise otherwise you don’t score an effect” ‘Patient groups are our expert patients’ Patients’ needs and expectations regarding involvement may vary depending on their condition and their prior experiences of involvement in medicines development Different needs of patient advocates depending on the condition they represent • ‘There are different needs behind different diseases’ 24
  25. 25. Information should be…        Accurate and up-to-date Quick and easy to navigate Easy to judge that it is high quality Developed by a credible source which is trustworthy, pan-European and driven by patients Quality stamp – impartial, trustworthy information Jargon free Simple, easy to understand and ‘straight to the point’ 25
  26. 26. Training courses content  Increasing content knowledge will increase patients’ confidence in getting involved in medicines development •   Support and training to work effectively work with industry and other stakeholders essential, eg, training in influencing skills “Rome wasn't built in a day”: a gradual approach is necessary to what is essentially a culture change    ‘What we need to do is try to educate our patient representatives to feel at home in this kind of tables and boards. So the people can consider them as peers.’ ‘Just like magic bullets are not always evident in medicines development, a training course alone is not going to ‘solve’ misconceptions and myths and help people to learn how to work effectively with one another.’ “Pick and mix”: Need for training about medicines R&D expressed but they do not necessarily want to be trained in all aspects. Advocates should be informed of their rights as patients • ‘The patient group should advocate also and promote patient’s rights because although patients might not have the knowledge on innovative medicines and development in the medicines scene but they have to be well informed of their rights 26
  27. 27. Training courses content Further information required on:          Science behind / scientific aspects of studies eg, HTA, Drug safety, Benefits and risks of involvement Importance of defining roles for patients in medicines development Empowering and supporting patients to become involved and engaged in medicines development and to judge whether information is useful Transparent information about the results of trials Patient-reported outcomes How the cost of medicines is determined How pharmaceutical companies decide where to invest their resources Scientific terminology • ‘I don’t have a scientific background at all, so when we try and get into discussions with scientists or pharma-companies or whoever it is that is dealing with drug development, be it governmental bodies or regulatory agencies, we lack this vocabulary. We lack the basic scientific knowledge that empowers us to be able to direct things in the way we want’. 27
  28. 28. Training courses format      Face to face elements provide “validation”; however, there is a danger of “decay” - not being able to use training soon after its delivery. Importance of communicating the roles that patients can play in medicines development Expert level courses can be difficult to follow: importance of prior preparation and guidelines for speakers Importance of refresher courses in a rapidly changing area For elements of the course to be delivered by fellow patient advocates •  ‘Patients believe more the experience from their peers.’ Case studies are useful: • From basic research to post-marketing • Examples of successful/unsuccessful involvement in research • To allow patient advocates to learn from each other 28
  29. 29. Delivery of training courses  Importance of using virtual methods of delivery 29
  30. 30. Recommendations to content development team Degree of emphasis placed on some modules compared to others That the time devoted to each module is clarified and communicated both to patients and to those developing the module Roles of patients within the medicines development process That the training course syllabus should more precisely define or describe the roles of patients in the medicines development process or where they don’t currently exist, what such roles might be That the current roles that patients have played within the medicines development process are documented and communicated within the training course – Examples of current good practice in involvement That patients with experience of involvement in medicines development are able to contribute to the teaching of the Expert Level course 30
  31. 31. Recommendations to content development team Quality, credibility and impartiality of the information and training produced by EUPATI To ensure that EUPATI content is viewed as credible and trustworthy that the process of producing, reviewing, assessing and user testing EUPATI content should be clearly outlined and made available Support and training for partnership working between patient advocates, industry and other key stakeholders To ensure that the course enables participants to have ‘hands on’ practice of the course content 31
  32. 32. Recommendations to content development team Recommendations on course content That course content clearly describes patients’ roles and responsibilities within medicines development Current low awareness but high interest levels in personalised / stratified medicine suggest that this is an area of great interest Content on the roles of the various key stakeholders in medicines development will be important to include as greater knowledge of this will facilitate greater patient involvement in medicines development Importance of course covering how patients can be involved in early research and development, eg, in setting research priorities Patient advocates are particularly interested in how to interpret clinical research evidence. This is an area of importance for the course 32
  33. 33. Recommendations to deployment and dissemination team Recommendations on application process for expert level training course Importance of ensuring that the course application process is as inclusive as possible, enabling as wide a range of participants in terms of their experience of medical research and medicines development, their perspectives and the condition they represent to take part 33
  34. 34. Work Package 3 team             University of Manchester Bella Starling – WP3 lead Suzanne Parsons – WP3 Project Manager Su-Gwan Tham – WP3 Project Assistant GlaxoSmithKline Kay Warner – WP3 co-lead Novo Nordisk Christine Mullan-Jensen – WP3 Deputy Co-lead EGAN / GAUK Kim Wever Celine Lewis Amgen, Genzyme, Roche, AstraZeneca, VFA 34
  35. 35. Get to know us! Web: www.patientsacademy.eu Twitter: @eupatients as well as:
  36. 36. Building Knowledge & Capacities for Patients’ Involvement in Medicines R&D Niels Westergaard, PhD, DSc Biopeople University of Copenhagen Denmark The project is receiving support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115334, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies.
  37. 37. Audiences: Advocacy leaders as well as the general public 1 2 3 EUPATI Certificate Training Programme Academic Modular Certificate Programme Patient Ambassadors in various committees, R&D teams, … Patient Journalists raising awareness Patient Trainers for patient communities & networks EUPATI Educational Toolbox   Educational tools for patient advocates Variety of distributable formats: Paper-based booklets, ppt presentations, eLearning, webinars, videos etc. 100 patient experts 12,000 patient advocates EUPATI Internet Library   Patients & the general public, eg, on specific aspects of the development process of medicines for patients with little health literacy experience Wiki, YouTube, films, cartoons, etc. 100,000 individuals
  38. 38. First version of the syllabus: 133 Topics F2F and eLearning •2 x 4 days F2F •240 h of eLearning Topics: Topics: Heavy: 2-6 h Heavy: 2-6 h or or Light: up to 2 h Light: up to 2 h
  39. 39. Learning outcomes condensed
  40. 40. Basic Principles of Medicine Discovery and Development The concept of Bioavailability and Bioequivalence
  41. 41. Deployment and Quality Assurance EUPATI Work Package 6 Update
  42. 42. WP6 Objectives     To implement the EUPATI expert, education and information programmes at European and national levels with the three patient audiences: 100 patient experts, 12,000 patient advocacy leaders and 100,000 patients at large To disseminate the availability of the programmes widely To assure high quality standards in development and implementation of training content and courses To monitor and evaluate on an on-going basis the quality and impact of the programmes’ delivery
  43. 43. WP6 Activities  Development and implementation of Communication Strategy for dissemination of programmes  Programme roll out for all 3 EUPATI audiences  Monitoring and evaluation on an on-going basis; the quality and impact of the programmes’ delivery (online tools, surveys, focus groups, interviews)
  44. 44. WP6 Deliverables
  45. 45. Progress update  Communication strategy being drafted – to be completed by end of November  Audience 1 - Patient Experts: Programme of F2F training component being developed Recruitment procedure being drafted – recruitment to be launched in January 2014 • •
  46. 46. Recruitment Audience 1 Eligibility       Individual Employee of a patient organisation who does not have the condition represented by the patient organisation Employee of a patient organisation who has the condition represented by the patient organisation Volunteer of a patient organisation who does not have the condition represented by the patient organisation Volunteer of a patient organisation who has the condition represented by the patient organisation Patient with a chronic and/or lifelong condition who is not affiliated to a patient organisation and who participates in policy/projects/activities/committees/etc. to represent his/her personal experience as patient and/or the perspective of a patient group Family member of a patient with a chronic and/or lifelong condition who is not affiliated to a patient organisation and who participates to policy/projects/activities/committees/etc. to represent the experience of his/her relative and/or the perspective of a patient group. OPEN to ALL EUROPEAN COUNTRIES
  47. 47. Recruitment Audience 1 Selection criteria 1) Individual motivation 2) Commitment to complete training 3) Commitment to use and apply learning 4) Good knowledge of English 1) Experience of being involved in medicines research and development 2) Experience related to the three EUPATI profiles 3) Country of origin – Open to all Europe 4) Disease area 5) Being a patient/informal carer
  48. 48. Selection procedure 1) Review of compliance with eligibility criteria + completeness of application package (WP6) 2) Selection done by ad-hoc Committee consisting of 5 members: 3 representatives of the EUPATI Consortium (1 patient organisation, 1 academia and 1 industry), one member of the EP and one member of the PAB. 3) Applications shortlisted to be revised independently by each member 4) F2F meeting to decide final assessment of applications and selection 5) Communication to all applicants on the result (WP6).
  49. 49. Next steps and questions Web: www.patientsacademy.eu Twitter: @eupatients as well as:

×